Literature DB >> 22021166

A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice.

Lisa D Berman-Booty1, Aaron M Sargeant, Thomas J Rosol, Robert C Rengel, Steven K Clinton, Ching-Shih Chen, Samuel K Kulp.   

Abstract

The transgenic adenocarcinoma of the mouse prostate (TRAMP) model is well established and offers several advantages for the study of chemopreventive agents, including its well-defined course of disease progression and high incidence of poorly differentiated carcinomas within a relatively short length of time. However, there is no consensus on the grading of prostatic lesions in these mice. In particular, agreement is lacking on the criteria for differentiating prostatic intraepithelial neoplasia (PIN) from well-differentiated adenocarcinoma, specifically as it relates to evidence of invasion. This differentiation is critical for evaluating the effects of putative chemopreventive agents on progression to neoplasia. Moreover, only one of the published grading schemes assigns numerical grades to prostatic lesions, which facilitate statistical analysis. Here, we review five currently available grading schemes and propose a refined scheme that provides a useful definition of invasion for the differentiation of PIN from well-differentiated adenocarcinoma and includes a numerical scoring system that accounts for both the most severe and most common histopathological lesions in each of the lobes of the prostate and their distributions. We expect that researchers will find this refined grading scheme to be useful for chemoprevention studies in TRAMP mice.

Entities:  

Mesh:

Year:  2011        PMID: 22021166      PMCID: PMC4271830          DOI: 10.1177/0192623311425062

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  16 in total

1.  Epithelial-stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model.

Authors:  Y Tani; A Suttie; G P Flake; A Nyska; R R Maronpot
Journal:  Vet Pathol       Date:  2005-05       Impact factor: 2.221

2.  A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model.

Authors:  Andrew Suttie; Abraham Nyska; Joseph K Haseman; Glenda J Moser; Theleria R Hackett; Thomas L Goldsworthy
Journal:  Toxicol Pathol       Date:  2003 Jan-Feb       Impact factor: 1.902

Review 3.  Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status.

Authors:  H Bonkhoff
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

4.  Pathologic progression of autochthonous prostate cancer in the TRAMP model.

Authors:  J R Gingrich; R J Barrios; B A Foster; N M Greenberg
Journal:  Prostate Cancer Prostatic Dis       Date:  1999-03       Impact factor: 5.554

5.  OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.

Authors:  Aaron M Sargeant; Robert C Rengel; Samuel K Kulp; Russell D Klein; Steven K Clinton; Yu-Chieh Wang; Ching-Shih Chen
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

6.  Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer.

Authors:  Aaron M Sargeant; Russell D Klein; Robert C Rengel; Steven K Clinton; Samuel K Kulp; Yoko Kashida; Mamoru Yamaguchi; Xingya Wang; Ching-Shih Chen
Journal:  Toxicol Pathol       Date:  2007-06       Impact factor: 1.902

7.  Prostate cancer in a transgenic mouse.

Authors:  N M Greenberg; F DeMayo; M J Finegold; D Medina; W D Tilley; J O Aspinall; G R Cunha; A A Donjacour; R J Matusik; J M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

8.  The TRAMP mouse as a model for prostate cancer.

Authors:  A A Hurwitz; B A Foster; J P Allison; N M Greenberg; E D Kwon
Journal:  Curr Protoc Immunol       Date:  2001-11

9.  Metastatic prostate cancer in a transgenic mouse.

Authors:  J R Gingrich; R J Barrios; R A Morton; B F Boyce; F J DeMayo; M J Finegold; R Angelopoulou; J M Rosen; N M Greenberg
Journal:  Cancer Res       Date:  1996-09-15       Impact factor: 12.701

Review 10.  Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.

Authors:  Scott B Shappell; George V Thomas; Richard L Roberts; Ron Herbert; Michael M Ittmann; Mark A Rubin; Peter A Humphrey; John P Sundberg; Nora Rozengurt; Roberto Barrios; Jerrold M Ward; Robert D Cardiff
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

View more
  17 in total

1.  Antiangiogenic therapy effects on age-associated matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses: a comparative study of prostate disorders in aged and TRAMP mice.

Authors:  Fabio Montico; Larissa Akemi Kido; Amanda Cia Hetzl; Raísa Mistieri Lorencini; Eduardo Marcelo Cândido; Valéria Helena Alves Cagnon
Journal:  Histochem Cell Biol       Date:  2014-02-22       Impact factor: 4.304

2.  Dietary Tomato or Lycopene Do Not Reduce Castration-Resistant Prostate Cancer Progression in a Murine Model.

Authors:  Joe L Rowles; Joshua W Smith; Catherine C Applegate; Rita J Miller; Matthew A Wallig; Amandeep Kaur; Jesus N Sarol; Salma Musaad; Steven K Clinton; William D O'Brien; John W Erdman
Journal:  J Nutr       Date:  2020-07-01       Impact factor: 4.798

3.  Dietary tomato and lycopene impact androgen signaling- and carcinogenesis-related gene expression during early TRAMP prostate carcinogenesis.

Authors:  Lei Wan; Hsueh-Li Tan; Jennifer M Thomas-Ahner; Dennis K Pearl; John W Erdman; Nancy E Moran; Steven K Clinton
Journal:  Cancer Prev Res (Phila)       Date:  2014-10-14

4.  Suppression of prostate epithelial proliferation and intraprostatic progrowth signaling in transgenic mice by a new energy restriction-mimetic agent.

Authors:  Lisa D Berman-Booty; Po-Chen Chu; Jennifer M Thomas-Ahner; Brad Bolon; Dasheng Wang; Tiffany Yang; Steven K Clinton; Samuel K Kulp; Ching-Shih Chen
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-28

5.  Impact of prostate inflammation on lesion development in the POET3(+)Pten(+/-) mouse model of prostate carcinogenesis.

Authors:  Grant N Burcham; Gregory M Cresswell; Paul W Snyder; Long Chen; Xiaoqi Liu; Scott A Crist; Michael D Henry; Timothy L Ratliff
Journal:  Am J Pathol       Date:  2014-11-22       Impact factor: 4.307

6.  β-Carotene 9',10' Oxygenase Modulates the Anticancer Activity of Dietary Tomato or Lycopene on Prostate Carcinogenesis in the TRAMP Model.

Authors:  Hsueh-Li Tan; Jennifer M Thomas-Ahner; Nancy E Moran; Jessica L Cooperstone; John W Erdman; Gregory S Young; Steven K Clinton
Journal:  Cancer Prev Res (Phila)       Date:  2016-11-02

7.  Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer.

Authors:  Lindsay K Ward-Kavanagh; Junjia Zhu; Timothy K Cooper; Todd D Schell
Journal:  Cancer Immunol Res       Date:  2014-05-06       Impact factor: 11.151

8.  The interactions of dietary tomato powder and soy germ on prostate carcinogenesis in the TRAMP model.

Authors:  Krystle E Zuniga; Steven K Clinton; John W Erdman
Journal:  Cancer Prev Res (Phila)       Date:  2013-04-16

9.  Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice.

Authors:  Lisa D Berman-Booty; Jennifer M Thomas-Ahner; Brad Bolon; Michael J Oglesbee; Steven K Clinton; Samuel K Kulp; Ching-Shih Chen; Krista M D La Perle
Journal:  Toxicol Pathol       Date:  2014-04-17       Impact factor: 1.902

10.  Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice.

Authors:  Jill P Smith; Timothy K Cooper; Christopher O McGovern; Evan L Gilius; Qing Zhong; Jiangang Liao; Alfredo A Molinolo; J Silvio Gutkind; Gail L Matters
Journal:  Pancreas       Date:  2014-10       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.